Skip to main content
Premium Trial:

Request an Annual Quote

New York Certifies Verinata's Lab, Paving Way for Firm to Offer Verifi NIPD in All 50 States

NEW YORK (GenomeWeb News) – Illumina announced late Thursday that Verinata Health has received a clinical laboratory permit from the State of New York for its laboratory, allowing the company to market its Verifi non-invasive prenatal diagnostic test in the state.

As a result, the test for trisomy 21, 18, and 13 and sex chromosome abnormalities can be offered by Verinata in all 50 states. Illumina, which purchased Verinata in February, noted that Verinata's laboratory is CLIA certified and CAP accredited.

During Illumina's recent second-quarter conference call, President and CEO Jay Flatley said that it plans to obtain clearance from the US Food and Drug Administration to sell Verifi as an in vitro diagnostic test and has begun discussions with the agency on a trial design.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.